Rockefeller Capital Management
CLDX icon

Rockefeller Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Rockefeller Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2K Buy
1,296
+145
+13% +$4.68K ﹤0.01% 3392
2026
Q1 		$36.5K Buy
1,151
+921
+400% +$25.1K ﹤0.01% 3433
2025
Q4 		$6.25K Buy
230
+211
+1,111% +$5.56K ﹤0.01% 3993
2025
Q3 		$492 Buy
+19
New +$440 ﹤0.01% 4269
2023
Q1 		– Sell
-37
Closed -$1K – 2309
2022
Q4 		$1K Hold
37
– – ﹤0.01% 3653
2022
Q3 		$1K Hold
37
– – ﹤0.01% 3681
2022
Q2 		$1K Buy
+37
New +$1.07K ﹤0.01% 3921
2022
Q1 		– Sell
-34
Closed -$1K – 3884
2021
Q4 		$1K Hold
34
– – ﹤0.01% 3624
2021
Q3 		$1K Buy
+34
New +$1.59K ﹤0.01% 3546

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's CLDX Position: Q2 2026 in Review

Rockefeller Capital Management increased its Celldex Therapeutics (CLDX) stake by 13% in Q2 2026, buying an estimated $4.68K and bringing the position to 1,296 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3392.

Rockefeller Capital Management first reported a position in CLDX in Q3 2021 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Rockefeller Capital Management held 1,296 shares of Celldex Therapeutics worth $48.2K as of Q2 2026.
  • Rockefeller Capital Management bought 145 Celldex Therapeutics shares in Q2 2026, an estimated $4.68K.
  • Celldex Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3392 holding.
  • Rockefeller Capital Management first reported a position in Celldex Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.